DELFT, The Netherlands, Oct. 15, 2002 (PRIMEZONE) -- Cardio Control NV has doubled its sales in the 3rd quarter compared with the same quarter last year. Sales amounted to EUR 2,4 mln compared to EUR 1,2 mln last year. For the first 9 months, sales rose to EUR 6,1 mln. The gross profit in the 3rd quarter was EUR 118.000 (2001: EUR 340.000 negative). For 2002, an increase in sales of approximately 50% is expected, resulting in annual sales of about EUR 10 mln. In this case Cardio Control expects to realize the highest net profit in its 20-year history.
Cardio Control designs, develops and sells worldwide medical diagnostic systems for heart and lung functions. Last year, the company introduced unique software for recording and analysing combined medical and patient data, for both centralized and remote usage. Customers are medical professionals and medical centers, with an increasing market in large clinics and hospitals. The most important product is Cardio Control's independently developed Stresstest ECG system for diagnosis of the heart function.
In a statement by managing director Dick G. van Luijk: "The rapid growth of our sales and improvement of our results shows that we are on the right track. For a satisfactory end of the year, our fourth quarter is still essential, just like it was in recent years. The average percentage of sales in the last quarter is at least 40% of the annual sales the last couple of years. There are no indications that this will be different this year, unless a war situation in the Middle East would occur and influence buying decisions and delivery obligations."
For questions regarding this press release: Investor Relations Department Cardio Control NV Mercuriusweg 1 2624 BC Delft Netherlands info@cardiocontrol.com Tel: (31) 15750.5000 Fax: (31) 15750.5055